SCHEMBL1899031

SCHEMBL1899031

CCC(C)S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.52
MAPT P10636 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
PSEN1 P49768 3/20 0.42
PSEN2 P49810 3/20 0.42
APH1B Q8WW43 3/20 0.42
NCSTN Q92542 3/20 0.42
APH1A Q96BI3 3/20 0.42
PSENEN Q9NZ42 3/20 0.42
PTGS2 P35354 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12605150 0.82 GBA1 (0.49) MAPTSMN1; SMN2CA1CA2TSHR
SCHEMBL881946 0.82 GBA1 (0.49) MAPTSMN1; SMN2CA1CA2TSHR
SCHEMBL13813079 0.80 MMP2 (0.47) CA1CA2KMT2AMMP1MMP2
SCHEMBL2918280 0.80 ENPP2 (0.48) MAPTCA1CA2KMT2A
SCHEMBL16852254 0.80 BCHE (0.46) TP53MAPTSMN1; SMN2CA1CA2
SCHEMBL9072788 0.80 MAPT (0.40) TP53MAPTSMN1; SMN2CA1CA2
SCHEMBL12674211 0.80 MMP2 (0.47) CA1CA2KMT2AMMP1MMP2
SCHEMBL21678791 0.79 CA1 (0.51) MAPTSMN1; SMN2CA1CA2PTGS2
SCHEMBL2446838 0.79 PSIP1 (0.52) TP53MAPTSMN1; SMN2HSD17B10ALDH1A1
SCHEMBL1368959 0.79 CA1 (0.48) TP53MAPTSMN1; SMN2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210078969-A1 Nrf2 Activating Compounds and Uses Thereof MIDCAP FINANCIAL TRUST 2021-03-18 US disclosed
US-20110112135-A1 Imidazo [1,2-A] Pyridine Compounds WYETH LLC 2011-05-12 US disclosed
EP-2231660-A1 IMIDAZO [1,2-A] PYRIDINE COMPOUNDS Wyeth LLC (US) 2010-09-29 EP disclosed
WO-2009086123-A1 IMIDAZO [1,2-A] PYRIDINE COMPOUNDS WYETH (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112135-A1 Imidazo [1,2-A] Pyridine Compounds NR1H2, NR1H3, NR1H4 TP53 4198/4885MAPT 4404/4885SMN1; SMN2 4711/4885
US-20210078969-A1 Nrf2 Activating Compounds and Uses Thereof NFE2L2, KEAP1, NQO1 TP53 935/4885MAPT 2271/4885SMN1; SMN2 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.